Evidence map›Paper›PMID 41755880›Full record

ArticleJACS Au2026

One-Pot Gateway to Quinazoline-Thiohydantoin Fused Scaffolds and Discovery of Their Antileukemic Activity.

Lena Kersting, Christoph Zippel, Lars Herrmann, Mohamed Elbadawi, Ean-Jeong Seo, Felix Heckmann, Mohamed E M Saeed, Angelika Gaube, Dhanir Tailor, Arpit Dheeraj and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACS Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lena KerstingDepartment of Chemistry and Pharmacy, Organic Chemistry Chair I and Interdisciplinary Center for Molecular Materials (ICMM), Friedrich-Alexander-University Erlangen-Nürnberg, Nikolaus Fiebiger-Straße 10, 91058 Erlangen, Germany.
Christoph ZippelDepartment of Chemistry and Pharmacy, Organic Chemistry Chair I and Interdisciplinary Center for Molecular Materials (ICMM), Friedrich-Alexander-University Erlangen-Nürnberg, Nikolaus Fiebiger-Straße 10, 91058 Erlangen, Germany.
Lars HerrmannDepartment of Chemistry and Pharmacy, Organic Chemistry Chair I and Interdisciplinary Center for Molecular Materials (ICMM), Friedrich-Alexander-University Erlangen-Nürnberg, Nikolaus Fiebiger-Straße 10, 91058 Erlangen, Germany.
Mohamed ElbadawiDepartment of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudingerweg 5, 55128 Mainz, Germany.
Ean-Jeong SeoDepartment of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudingerweg 5, 55128 Mainz, Germany.
Felix HeckmannDepartment of Chemistry and Pharmacy, Organic Chemistry Chair I and Interdisciplinary Center for Molecular Materials (ICMM), Friedrich-Alexander-University Erlangen-Nürnberg, Nikolaus Fiebiger-Straße 10, 91058 Erlangen, Germany.
Mohamed E M SaeedDepartment of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudingerweg 5, 55128 Mainz, Germany.
Angelika GaubeDepartment of Molecular and Clinical Pharmacy, Friedrich-Alexander-Universität Erlangen-Nürnberg, Nikolaus-Fiebiger-Straße 10, 91058 Erlangen, Germany.
Dhanir TailorDepartment of Cell, Developmental and Cancer Biology, Center for Experimental Therapeutics, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97201 United States.
Arpit DheerajDepartment of Cell, Developmental and Cancer Biology, Center for Experimental Therapeutics, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97201 United States.ORCID https://orcid.org/0000-0002-1034-5075
Sanjay V MalhotraDepartment of Cell, Developmental and Cancer Biology, Center for Experimental Therapeutics, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97201 United States.ORCID https://orcid.org/0000-0003-4056-5033
Susanne MuehlichDepartment of Molecular and Clinical Pharmacy, Friedrich-Alexander-Universität Erlangen-Nürnberg, Nikolaus-Fiebiger-Straße 10, 91058 Erlangen, Germany.
Thomas EfferthDepartment of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudingerweg 5, 55128 Mainz, Germany.ORCID https://orcid.org/0000-0002-2637-1681
Svetlana B TsogoevaDepartment of Chemistry and Pharmacy, Organic Chemistry Chair I and Interdisciplinary Center for Molecular Materials (ICMM), Friedrich-Alexander-University Erlangen-Nürnberg, Nikolaus Fiebiger-Straße 10, 91058 Erlangen, Germany.ORCID https://orcid.org/0000-0003-4845-0951

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In drug discovery, fusing bioactive heterocyclic frameworks leads to new analogs with improved properties. Quinazoline and thiohydantoin are prominent heterocycles, recognized for their diverse pharmacological profiles. Although quinazolines fused with various heterocycles are present in numerous clinical drugs, quinazoline-thiohydantoin fused frameworks, along with their synthetic approaches, remain unreported. Here, we introduce a transition metal-free, one-pot approach that enables the efficient and high-yielding synthesis (up to 92% yield) of this previously unexplored class of heterocyclic compounds. A streamlined three-step domino reaction, enabling the

Indexed as

domino reactionfused quinazoline–thiohydantoinsheterocycles synthesisin silico analyseskinome screeningmultidrug-resistant leukemiaone-pot reaction

Identifiers

PMID41755880
PMCPMC12933347

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.